Biovica has secured SEK 122 million through a capital raise to scale up sales. The core of the initiative is DiviTum TKa, a blood-based test that measures cell division and provides healthcare providers treatment-effect insights in days instead of months. The capital will primarily be used to accelerate sales in the US and build capacity for larger volumes. We reached out to CEO Anders Rylander for a comment.

Read the full interview at biostock.se:

SEK 122 million gives Biovica the power to scale up globally

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!  

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Läs mer på BioStock

Ämnen i artikeln

Biovica International B

Senast

0,35

1 dag %

−2,54%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån